Search

Search Results

• HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA AND SICKLE CELL DISEASE: EXPERIENCE OF MEDITERRANEAN INSTITUTE OF HEMATOLOGY IN A MULTI-ETHNIC POPULATION.

  Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

  e2009027

  2009-12-26

  1669

  PDF: 720

  HTML: 2916

• POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.

  Sinem Başak Tan Öksüz, Güldane Cengiz Seval, Klara Dalva, Selami Koçak Toprak

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.028

  704

  PDF: 389

  Suppl. Files: 120

  HTML: 112

• COVID-19 post hematopoietic cell transplant, a report of 11 cases from a single center.

  Afadil Adam

  e2020070

  2020-08-29

  https://doi.org/10.4084/mjhid.2020.070

  1704

  PDF: 1121

  HTML: 279

• COST OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INDIA

  Sanjeev Kumar Sharma, Dharma Choudhary, Nitin Gupta, Mayank Dhamija, Vipin Khandelwal, Gaurav Kharya, Anil Handoo, Rasika Setia, Arpita Arora

  e2014046

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.046

  2669

  PDF: 967

  HTML: 4703

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1083

  PDF: 843

  HTML: 238

• EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES

  Kjeld Schmiegelow

  e2011020

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.020

  2193

  PDF: 797

  HTML: 1627

  Figure 1: 182

  Table 1: 205

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3771

  PDF: 1661

  HTML: 11590

  Figures Haase: 198

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1514

  PDF: 1335

  HTML: 113

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  1903

  PDF: 1631

  HTML: 123

• ANALYSIS OF PROGNOSTIC RISK FACTORS OF BLOODSTREAM INFECTIONS IN BEIJING COMMUNITIES: A RETROSPECTIVE STUDY FROM 2015 TO 2019

  Yan Liu, Beichen Cui, Chunmei Pi, Xiaohong Yu, Zhiwei Liu, Xiang Li, Liping Ma, Cong Wang

  e2021060

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.060

  843

  PDF: 351

  HTML: 128

• Is there a better therapeutic time window from diagnosis to treatment elderly acute myeloid leukemia patients receiving hypomethylating agents?

  Salvatore Perrone

  e2024055

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.055

  576

  PDF: 799

  HTML: 98

• ADVANCES IN THE TREATMENT OF MALARIA

  Francesco Castelli, Lina Rachele Tomasoni, Alberto Matteelli

  e2012064

  2012-10-03

  https://doi.org/10.4084/mjhid.2012.064

  2842

  PDF: 1122

  HTML: 5991

• Evaluating the use of meropenem in hematologic patients with febrile neutropenia A retrospective observational single-cohort study

  R.A. Stuurman, E. Jong, P.C.R. Godschalk, M.F. Corsten, J.E. Nagtegaal

  e2023067

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.067

  977

  PDF: 448

  HTML: 134

• Morphologic leukemia-free state after venetoclax-based therapy in acute myeloid leukemia is associated with high relapse despite preserved short-term survival

  Kenta Motegi

  e2026048

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.048

  211

  PDF: 224

  HTML: 16

• FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.

  Andrea Gallamini, Anna Borra

  e2017029

  2017-04-15

  https://doi.org/10.4084/mjhid.2017.029

  3316

  PDF: 1237

  HTML: 2199

• CIRCRNA CIRCEHBP1 REGULATES THE MATURATION OF MIR-129 TO INCREASE THE CHEMORESISTANCE OF CANCER CELLS TO ADRIAMYCIN IN ACUTE MYELOID LEUKAEMIA

  Hong Li, Kehong Bi, Saran Feng, Yan Wang, Chuansheng Zhu

  e2022062

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.062

  607

  PDF: 494

  HTML: 190

• COVID-19 induces prolonged immunological exhaustion leading to relapse of hematological malignancies except in hematopoietic cell transplant recipients

  SUPARNO CHAKRABARTI, Snigdha Banerjee, Mahak Agarwal, Gitali Bhagawati, Nilanjan Saha, SARITA JAISWAL

  e2025042

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.042

  1024

  PDF: 705

  HTML: 114

• The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients

  Hesham Elsabah, Mahmood B. Aldabt, Ruba Taha, Dina Sameh Soliman, Halima Elomri, Feryal Ibrahim

  e2020082

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.082

  971

  PDF: 361

  HTML: 196

• Acute Hemolytic Anemia Following Rasburicase in a Very Late Post-Transplant Relapse of Acute Myeloid Leukemia

  Gianluca Cavallaro, Federico Lussana, Marco Frigeni, Maria Caterina Micò, Alessandra Algarotti, Anna Grassi, Orietta Spinelli, Chiara Pavoni, Elena Oldani, Alessandro Rambaldi

  e2026003

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.003

  573

  PDF: 449

  Html: 93

• Bacillus cereus in the neutropenic patient: case report in a patient with myelodysplastic syndrome and review of the literature

  Mariam Markouli, Sevastianos Chatzidavid, Dimitra Vlachopoulou, Nefeli Giannakopoulou, Amalia Anastasopoulou, Nora-Athina Viniou, Panagiotis Diamantopoulos

  e2022071

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.071

  935

  PDF: 747

  HTML: 200

• Managment of Relapsed/Refractory ALL With Inotuzumab During COVID-19. A Casr Report

  Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mulè, Robin Foà, Maurizio Martelli, Gabriella D'Ettorre, Saveria Capria, Sabina Chiaretti

  e2022043

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.043

  1342

  PDF: 568

  HTML: 219

• MALNUTRITION, SEPSIS AND TUMOR LYSIS SYNDROME ARE ASSOCIATED WITH INCREASED RATE OF ACUTE MORTALITY IN MATURE B CELL NON-HODGKIN LYMPHOMA IN PEDIATRIC POPULATION- STUDY FROM TERTIARY CARE HOSPITAL IN PAKISTAN

  Raheela Mansoor

  02019043

  2019-06-24

  https://doi.org/10.4084/mjhid.2019.043

  1402

  PDF: 1025

  HTML: 284

• A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

  Mauro Passucci, Francesca Fazio, Maria Teresa Petrucci

  e2023012

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.012

  882

  PDF: 940

  HTML: 412

• WHO HAS THERAPY-RELATED AML?

  Robert Gale, John M. Bennett, F. Owen Hoffman

  e2017025

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.025

  3121

  PDF: 4308

  HTML: 784

• ROLE OF STEM CELL FACTOR IN THE REACTIVATION OF HUMAN FETAL HEMOGLOBIN

  Marco Gabbianelli, Ugo Testa

  e2009009

  2009-11-12

  1118

  PDF: 475

  HTML: 4480

• TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

  Luis Anibarro, Alberto Pena

  e2014026

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.026

  3269

  PDF: 1236

  HTML: 8105

• EPIDEMIOLOGY OF CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE INFECTIONS IN MEDITERRANEAN COUNTRIES

  Corrado Girmenia, Martina Canichella, Alessandra Serrao

  e2016032

  2016-06-01

  https://doi.org/10.4084/mjhid.2016.032

  4940

  PDF: 1586

  HTML: 2381

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1571

  PDF: 1204

  HTML: 189

• Editorial : INTRODUCING MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES

  Giuseppe Leone, Luigi Maria Larocca, Eligio Pizzigallo

  e2009001

  2009-06-22

  3323

  PDF: 582

  HTML: 661

• FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells

  Eugenio Galli, Filippo Frioni, Tanja Malara, Enrico Attardi, Silvia Bellesi, Stefan Hohaus, Simona Sica, Federica Sorà, Patrizia Chiusolo

  e2024029

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.029

  951

  PDF: 1206

  HTML: 110

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4245

  PDF: 1517

  HTML: 447

• GUT COLONIZATION WITH CARBAPENEM RESISTANT ENTEROBACTERIACEAE ADVERSELY IMPACTS THE OUTCOME IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RESULTS OF A PROSPECTIVE SURVEILLANCE STUDY

  SUPARNO CHAKRABARTI

  e2018025

  2018-05-01

  https://doi.org/10.4084/mjhid.2018.025

  3676

  PDF: 1246

  HTML: 397

• DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE

  Paola Zanotti, Claudia Chirico, Maurizio Gulletta, Laura Ardighieri, Salvatore Casari, Eugenia Quiros Roldan, Ilaria Izzo, Gabriele Pinsi, Giovanni Lorenzin, Fabio Facchetti, Francesco Castelli, Emanuele Focà

  e2018040

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.040

  3677

  PDF: 1283

  HTML: 728

  Figure 2: 452

  Figure 1: 3117

• HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS

  Emanuele Angelucci, Federica Pilo, Clara Targhetta, Martina Pettinau, Cristina Depau, Claudia Cogoni, Sara Usai, Mario Pani, Laura Dessì, Donatella Baronciani

  e2009015

  1398

  PDF: 489

  HTML: 3958

• ANORECTAL COMPLICATIONS DURING NEUTROPENIC PERIOD IN PATIENTS WITH HEMATOLOGIC DISEASES

  Soner Solmaz

  e2016019

  2016-03-01

  https://doi.org/10.4084/mjhid.2016.019

  3023

  PDF: 963

  HTML: 1566

• CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

  Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi

  e2010017

  2010-06-18

  https://doi.org/10.4084/mjhid.2010.017

  1662

  PDF: 720

  HTML: 2338

• Successful Outcomes of Severe COVID-19 in Patient with Chronic Lymphocytic Leukemia: Diagnostic Challenges in Immunocompromised Hosts COVID-19 in cancer patients

  Alexandre Malek

  e2020044

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.044

  1184

  PDF: 783

  HTML: 218

• BACTERIAL BLOOD STREAM INFECTIONS NEGATIVELY IMPACT ON OUTCOME OF PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION: 6 YEARS SINGLE-CENTRE EXPERIENCE

  Michele Malagola

  e2017036

  2017-06-20

  https://doi.org/10.4084/mjhid.2017.036

  2402

  PDF: 811

  HTML: 1063

• TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL

  Giorgia Sulis, Alberto Roggi, Alberto Matteelli, Mario C. Raviglione

  e2014070

  2014-10-27

  https://doi.org/10.4084/mjhid.2014.070

  6944

  PDF: 3916

  HTML: 24881

• Hematogenous Disseminated Pulmonary Tuberculosis in an Elderly Patient with Acute Myeloid Leukemia: A Case Report

  Yu xi Ding, Xiao Dong Liu, wenqiang kong

  e2026010

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.010

  533

  PDF: 476

  HTML: 207

• Pseudo-differentiation syndrome

  Dina Khalaf, Fathi Jehani

  e2011061

  2011-12-15

  https://doi.org/10.4084/mjhid.2011.061

  1346

  PDF: 659

  HTML: 10846

  Figure 1: peripheral blood showing myeloblasts with auer rods: 117

  Figure 2: CXR upon presentation to the hospital- no infiltrates nor consolidation changes: 105

  Figure 3: CXR showing pulmonary infiltartes with consolidation: 136

  Figure 4: CXR after starting steroid therapy- where the infiltrates have melted away: 109

  Figure 5: barograph showing the rising TLC ad ANC values- associated with worsening symptoms and increasing pulmonary infiltrates in CXR: 119

• Bone marrow involvement in a patient with alpha heavy chain disease:Response to tetracycline treatment

  Zahit Bolaman, Irfan Yavasoglu, Gokhan Sargin, Gurhan Kadikoylu, Firuzan Kacar Doger

  e2012034

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.034

  1205

  PDF: 1013

  HTML: 3403

• IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?

  Fahad Al-Eidan

  e2015029

  2015-04-19

  https://doi.org/10.4084/mjhid.2015.029

  1662

  PDF: 819

  HTML: 1468